Introduction
Regenerative medicine and tissue engineering are novel ways of treating acute and chronic diseases and are expected to enable the regeneration of tissue-specific functions. Because they are derived from human cells and tissues, the products are regulated as biologics that differ significantly from chemically synthesized drugs [1] . Recently, human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient have been regulated as human cells, tissues, and cellular and tissuebased products (HCT/Ps) in the United States (US) [2] , somatic cell therapy medicinal products or tissue-engineered products of advanced therapy medicinal products (ATMPs) in the European Union (EU) [3] , and cell/tissue-engineered products in Japan [4, 5] . Although these innovative advanced products primarily belong to the class of cell-based medical products for human use because they contain or consist of living cells or tissues, the products have two lateral aspects that allow them to be classified as drugs or medical devices according to the primary mode of action [6] and to be divided based on their origins as autologous and allogeneic [2e5] .
The definition of human cells and tissue products is similar but definitely not the same among the US, the EU, and Japan. The categorization or classification of human cells and tissue products is different among the US, the EU, and Japan [2e5] .
The therapeutic areas of approved human cells and tissue products vary from epidermal transplantation for emergency use [7, 8] , fibroblast injection for cosmetic surgical repair [9] , transplantation of tissue engineered cartilage [10e12], chondrocyte injection for orthopedic trauma [10, 11, 13 ] to activated mononuclear cell infusion for cancer treatment [14, 15] . The premarket evaluation of human cells and tissue products also varies, including the accelerated approval [11] , the humanitarian device exemption (HDE) [7] , the ATMP approval [10, 12, 15] , and the premarket approval [8e10,14] .
However, few studies have been conducted to elucidate the similarity or difference of the definition, category, premarket approval evaluation by regulatory authorities, and adverse events of human cells and tissue products. Recently, we have published the regulation of allogeneic human cells and tissue products [16] that are seven products on the market in the US only, and five of seven products had evaluated using comparative clinical trials with control treatment. Otherwise, there is no such detailed study of autologous human cells and tissue products. In these products, some products had been on the market as cell bank and the target population of some indications such as orphan diseases is very small. We developed a hypothesis about premarket approval evaluation of autologous human cells and tissue products that may be limited information, and may need a special market evaluation system.
The aim of this study was to provide detailed information to enhance the discussion regarding the regulatory approval of human autologous cells and tissue products which have little consideration about transplant graft rejection, and microbiological or viral infections.
Materials and methods
This study included the autologous cells and tissue products in the US, the EU or Japan by October 2013. The classifications and definitions of the human cells and tissue products were different among these two countries and the EU. In the US, the HCT/Ps were defined under sections 351 and 361 of the Public Health Service (PHS) Act (42 the United State Code) according to Title 21, Part 1271.10 and 1271.20 in the Code of Federal Regulation (21CFR1271), respectively [2] . We focused on the HCT/Ps under section 351 of the PHS Act which require premarket approval. The HCT/Ps under section 361 were excluded due to the absence of a requirement for premarket approval. The information on the definition and classification of HCT/Ps was obtained from the Food and Drug Administration (FDA) website [2] . The information on the approved HCT/Ps was obtained from the FDA website of the approved cell therapy products [17] and the listing of the Center for Devices and Radiological Health (CDRH) HDE [18] . The information from the review reports for each HCT/P was obtained from the appropriate FDA websites for Carticel™ [19] , Epicel ® [20] , Provenge ® [21] , and Laviv ® [22] . In the EU, an ATMP is defined as a gene therapy medicinal product, a somatic cell therapy medicinal product, and a tissue-engineered product. We focused only on ATMPs because of a similar definition for HCT/Ps under section 351 of the PHS Act in the US. The information on the definition and classification of the ATMPs was obtained from the European Medicine Agency (EMA) website [3] . The information from the public assessment report for ChondroCelect ® [23] , MACI [24] , and Provenge [25] [5] . The information from the review report for JACE [27] and JACC [28] were obtained from the website of the Pharmaceuticals and Medical Devices Agency (PMDA). The generic name and trade name, cell origin, approval date, market authorization holder, authority, indication and category of medicinal product for each product were obtained from the regulatory information. The history of regulatory action, preapproval and postapproval clinical evaluation was obtained from the appropriate review reports or public assessment reports.
Results

Approved autologous cells and tissue products in the US, the EU, and Japan
A total of nine approved autologous cells and tissue products in the US, the EU, and Japan were on the market as of October 2013 (Table 1 , Fig. 1 ). Four products derived from autologous chondrocytes for the repair of cartilaginous defects of the femoral condyle were approved by the FDA, the EMA, and the MHLW in Japan. Two products derived from autologous epidermis for use in patients with deep dermal or full thickness burns (total body surface area greater than or equal to 30%) were approved by the FDA and the MHLW. Two products derived from autologous peripheral blood mononuclear cells to treat hormone refractory prostate cancer and a product from autologous fibroblasts to improve the appearance of nasolabial wrinkles were approved by the FDA and the EMA.
Classification, definition, and regulation of human cells and tissue products in the US, the EU, and Japan
The human cells and tissue products were classified and defined as HCT/Ps in the US, as ATMPs in the EU and as cell/ tissue-engineered products in Japan ( Table 2 ). The approved HCT/Ps were regulated under sections 351 of the PHS Act according to 21CFR1271, which were categorized as drug or biological product or medical device. The approved AMTP was regulated as the somatic cell therapy medicinal product and the tissue engineering product under Regulation (EC) No 1394/2007 of the European Parliament and the Council of 13 November, 2007, which was categorized as medicinal product (drug). In Japan, the approved cell/tissue-engineered products were regulated as medical devices by adapting existing legislation under clause 2 of the Pharmaceutical Affairs Law (PAL). The PFSB notification of No. 0280003/2008 describes the definition of cell/ tissue-engineered products, and the quality and safety of these autologous products.
3.3. History of regulatory action, preapproval and postapproval clinical evaluation of autologous human cells and tissues products in the US, the EU, and Japan
In the US, prior to issuing of the guidance regarding manipulated autologous structural (MAS) cells on May 28, 1996 [29] After being submitted as BLA in 1996, the product derived from autologous chondrocytes, autologous cultured chondrocytes (Carticel™, Genzyme Tissue Repair, Cambridge, MA, US) was approved on August 22, 1997 for the accelerated approval of biological products for serious or life-threating illnesses (21CFR601.40) [30] using the Swedish clinical experience of 153 patients and the US [33] . Currently, the postapproval clinical study titled the registry of Sipuleucel-T therapy in men with advanced prostate cancer (PROCEED) is ongoing to enroll 1500 patients ( Table 3 ). The product of autologous fibroblasts, Azficel-T (Laviv Table 3 ). The FDA recommended that a postmarket registry study should be conducted to access the risk of skin cancer in the area of the Laviv ® injection and immunemediated hypersensitivity reactions in 2700 subjects. In the EU, the product of characterized viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (ChondroCelect ® , Tigenix NV, Leuven, Belgium) were first approved as an ATMP on October 5, 2009 using the randomized, controlled clinical trial data of 118 patients (ChondroCelect ® , 57 patients vs. microfracture, 61 patients) and the compassionate use data of 334 patients followed by pharmacovigilance. ChondroCelect ® resulted in better structural repair, as assessed by histmorphometry (p ¼ 0.003) and overall histologic evaluation (p ¼ 0.0103) ( Table 3) . Matrix-applied characterized autologous cultured chondrocytes (MACI, Genzyme Biosurgery ApS, Kastrup, Denmark) consists of autologous chondrocytes, seeded on a collagen membrane of porcine origin (type I/III ACI-Maix) which is a CE marking device in the EU. MACI is an ATMP defined as combined tissue-engineering product. Prior to the introduction of the Regulation (EC) 1394/ 2007 and during the ATMP transitional period, MACI was available in certain European countries (i.e. Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, and the United Kingdom) and Australia, in accordance with national legislation since 1998. When experience. MACI was superior compared to standard care of microfracture with symptomatic cartilage defects the knee with a range of defect sizes from 3.0 to 20.0 cm 2 (grade III and IV modified outerbride scale), regarding mean improvement of pain and function (Table 3) . Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (Sipuleucel-T) (Provenge, Dendreon UK Ltd., London, UK) was submitted through the centralized procedure on December 30, 2011, and approved as the ATMP on September 6, 2013 using the data from 14 clinical trials with a total of 1382 patients and post-market registry of 28 patients. The pivotal study (IMPACT study) with 512 patients (Provenge ® -arm, 341 patients vs. Placebo-arm, 171 patients) be submitted to EMA was same data as the FDA approved in 2010 (Table 3) .
In Japan, a surgical/orthopedic material involving autologous cultured epidermis (JACE, Japan Tissue Engineering Co., Ltd., Aichi, Japan) was submitted as New Medical Device Application on October 6, 2004, and was approved on October 29, 2007 using the clinical trial data of two patients to confirm the efficacy and safety of the product in the treatment of severe burns. Due to the extremely limited number of patients in the clinical trial, the conditions for approval were attached such as a postapproval clinical trial with 30 patients and a postmarket survey for all patients treated with JACE for seven years (Table 3) .
Human autologous cells and tissues involving autologous cultured chondrocytes (JACC, Japan Tissue Engineering Co., Ltd., Aichi, Japan) was submitted as New Medical Device Application on August 24, 2009 , and was approved on July 22, 2012 using the clinical trial data of 32 patients to confirm the efficacy and safety of the product in the treatment of traumatic cartilage deficiency and osteochondritis. Due to the limited number of patients in the clinical trial, the conditions for approval were attached such as a postmarket survey for all patients treated with JACE for seven years (Table 3) .
Regulatory pathways and legislation issuance
In the US, since the first guidance on manipulated autologous cells was issued in 1996 [29] , many rules regarding HCTPs were issued. In 1997, FDA proposed a new approach to the regulation of HCTPs, which would establish in 21CFR1271 a comprehensive regulatory program. Final rules of establishment registration and listing in 2001, final rules of donors eligibility as well as inspection and enforcement for current good tissue practice (CGTP) in 2004, and final rules of donor screening, testing, and labeling in 2007 are the most important guidance for HCTPs regulations (Table 4) .
In the EU, the medicinal products directive was issued in 2001. The regulation of medicinal products for human use regarding EUwide marketing authorization was issued in 2004 and ATMP regulation was issued in 2007. According to ATMP regulation, ATMP, other than tissue engineering products which were legally on the EU market in accordance with national legislation on December 30, 2008, shall be authorized using central application no later than December 30, 2011. Tissue engineering products which were legally on the EU market in accordance with national legislation on December 30, 2008, shall be authorized using central application no later than December 30, 2012 [3] (Table 4) .
In Japan, a notification for quality and safety assurance for medical devices or drug products using cells or tissues was issued in 1999 and the confirming application prior to initiating clinical trials had continued until 2011. In 2008, notifications for quality and safety assurance for medical devices or drug products with processed autologous and allogeneic human-derived cells and tissue were issued [4, 5] (Table 4) . The pathways of the nine approved autologous human cells and tissue products for market authorization in the US, the EU, and Japan demonstrated that the issuance of major regulations and guidance, especially in the US, induced various market authorizations, such as the accelerated application approval, the HDE approval, and the BLA (Fig. 1) .
Safety information: recalls, alters, notification, and adverse event reports
Recalls regarding two products were enforced three times ( Table 5 ). The Dear Healthcare Professional Letter from the manufacturer of Carticel™ was issued on March 2000, which was Confirming application prior to initiating clinical trial. Records and documents retention of specified biologics for 30 years and biologics for 10 years 2000
Quality and safety assurance for drug products manufactured using human-or animal-derived components as raw materials, Appendix 1: Basic policies for handling and using drug products using cells and tissue; Appendix 2: Guidance regarding quality and safety assurance for drug products manufactured by processing human-derived cells and tissue. intended to narrow the indication [35] (Table 1) . Sixty three adverse event reports regarding Epicel ® from Manufacture and User Device Experience (MAUDE) of the FDA were 54 death reports, seven other serious adverse events, and the rest of reports from publication in the United Kingdom. Of 63 reports, three reports mentioned that three serious adverse events as severe fever and poor outcome were possibility of related to use the Epicel ® . One adverse event report for Carticel™ was voluntarily submitted as high fever at one day after transplantation to MAUDE of the FDA. In the EU and Japan, there was no recall and serious adverse event report.
Discussion
Our findings show that there were various kinds of premarket application approval for autologous human cells and tissue products, that the preapproval clinical evaluations were conducted with small population or using clinical experience, while five of the seven allogeneic human cells and tissue products were approved for market authorization using relatively larger clinical trials [36e40]. The results suggest that the products may lead to postmarket-orientated evaluation rather than premarket-oriented evaluation.
Our survey of nine autologous human cells and tissue products approved by October 2013 shows that the definitions for human cells and tissue products were definitely not same among the US, the EU, and Japan, but still compatible for defined products. In the US, the distinction between HCT/Ps under sections 351 and 361 is based on the degree of risk posed by the products: for low risk products, so-called 361 products focus on minimizing the risk of transmission of infectious diseases, and higher risk HCT/Ps, socalled 351 products present in their processing or use. The 361 Medical device alters and notifications: http://www.info.pmda.go.jp/mdevices/md-others.html (in Japanese). a A recall is an action taken to address a problem with a medical device that violates FDA law. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health. b Class 1 recall: a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death; Class 2 recall: a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote; Class 3 recall: a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
products must be minimally manipulated, perform the same basic function in the donor as recipient (homologous use), not be combined with other agents and not have systemic affect [2] . Furthermore, the definition of ATMPs and cell/tissue-engineered products in the EU and Japan, respectively, is easily understandable [3, 5] . [42] . In contrast, Japan had adapted existing legislation under clause 2 of the PAL [43, 44] . Currently, in Japan, the revised PAL which is changed the name of legislation as "Medicinal Products and Medical Device Law" is reformed the category of human cells and tissue products to "regenerative medicine products" [45] .
A significant regulatory impact occurred in 1996 in the US, when the first guidance of MAS cells was issued [29] . At that time, some MAS cell products, including Epicel ® , Carticel™ and Laviv ® , were on the market as banked human tissue (Fig. 1) . Epicel ® and Carticel™ were withdrawn from marketing in 1996 [19, 20] , and Laviv ® in 1999 [46] . Depending on the primary mode of action and the indication, the manufacturers can choose one of three different premarket approval applications: the accelerated approval application of biological products for serious or life-threating illness as for Carticel™, the HUD designation and HDE approval application as for Epicel ® , and the IND application for conducting clinical trials following BLA application as for Laviv ® and Provenge ® . In the EU, a similar regulatory impact occurred in 2007, when the ATMP regulation was issued [3] . At the time, MACI were available in certain European countries and Australia in accordance with national legislations since 1998 [24] . After receiving a several scientific advices from EMA's Committee for Medical Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT), MACI was submitted through the centralized procedure on September 1, 2011, and was approved as an ATMP on September 6, 2013. Otherwise, both the products of JACE and JACC underwent new medical device approval applications [27, 28] , and ChondroCelect ® and Provenge went through the centralized applications for ATMPs [23, 25] for market authorization. These products might be applicable to the fast track application for a life-threatening or chronically debilitating condition similar to that for an orphan drug and medical device application to use in a small patient population, which is 50,000 patients in Japan [47] and no more than 5 in 10,000 people in the EU at the time of submission of the rare disease (orphan) designation application [48] . Furthermore, the accelerated approval system of specifically targeted biological products for serious or life-threating illnesses [30, 49] should be focused on implementing relevant regulation in the EU and Japan for fast application to patients. In Japan, the regulatory reform of medical products has just implemented after the notice through official gazettes on November 27, 2013. The new legislation will be available the conditional/time-limited approval system for regenerative medicine products [45] . For premarket approval authorization, safety and efficacy data from nonclinical and clinical studies are the most important information to be included for the examination of submitted documents or dossiers. In the present study, we focused on which preapproval clinical evaluation had been conducted by the relevant regulatory authorities. Clinical experience data [19, 20] were used to evaluate the safety of Epicel ® and Carticel™ in the US, which were on the market prior to their applications because these products were distributed as banked human tissue. The data from two pivotal trials with five supporting trials for Laviv ® [22] were evaluated; however, nonclinical data were not submitted by the sponsor because this product had been on the market as cosmetic treatment for four years without FDA premarket approval, and because an appropriate animal model for wrinkles was unavailable, and much clinical information was available. As biologics and ATMPs applications, the primary endpoints of Provenge ® [21, 25] ,
, and MACI [24] were evaluated.
These products were approved as an ATMP in the EU or as HCTPs in the US, but no products have confirmed the primary endpoint in two clinical trials. According to the clinical reviewer's comments from the clinical reviews of US FDA or public assessment report of EMA, these products needed additional efficacy information after premarket approval because two clinical trials are typically required to evaluate the primary endpoint in new drugs and biologics [22, 23] . After premarket approval, postmarket registration and surveillance have been conducted according to the condition of approval: a postmarket clinical trial and surveillance of all patients for seven years for JACE [27] and JACC [28] , a 1500-patient registry in US [21] and EU registry [25] for Provenge ® , a 2700-patient registry for Laviv ® [22] , a postmarket safety and efficacy study for ChondroCelect ® [23] , and a postmarket safety and efficacy study for MACI [24] . During the postmarket surveillance, only three recalls were enforced for Carticel™ and Provenge ® . The FDA showed that a total of 497 adverse events among 294 patients receiving Carticel™ were reported from 1996 to 2003 [50] and a serious adverse event was voluntarily reported from user facility. Furthermore, 63 serious adverse events for Epicel ® were reported, while no serious adverse event was reported on the other autologous human cells and tissue products. Typical premarket-oriented evaluation is timeconsuming, expensive, and needs abundant human resources. The advantages of postmarket-oriented review are easier access than conducting clinical trial for patients, and would provide much information on safety and efficacy from a real world of clinical experience and update safety information. Therefore, the latter should be employed in some specific occasions such as orphan disease and autologous human cells and tissue products. This should be along the line with what is advocated in "Adaptive licensing" [51] . We believe that adaptive licensing's character of small population disease should fit the autologous human cells and tissue products, because the products are derived from autologous cells and tissue and applied specific area such as unmet medical needs which an ordinary drug or medical device do not enable to cover. A similar approval system as adaptive licensing, the conditional/time-limited approval system for regenerative medicine products in Japan would accelerate the development of regenerative medicine products. For HCTPs, the FDA has focused on a risk-based approach to examine the risks and benefits [52] . In autologous HCT/Ps, it considers three major hazards: donor infection and contamination during processing or manufacturing, allergic reaction at the administration site by the processing materials, and tumorigenic potential. The hazards are lessened by complying with the guidance for donor eligibility [53] and current Good Tissue Practices [54] . Warnings and precautions regarding foreign materials, animalderived products, irritants and/or antibiotic use are described in the labeling of Laviv ® [55] , JACE [56] , JACC [57] , Epicel ® [58] , and MACI [59] , and other information of ChondroCelect ® [60] , Provenge ® [61, 62] and Carticel™ [63] is described in the product labeling. Although the tumorigenic potential is believed rare, the possibility cannot be completely excluded. Therefore, in vivo tumorigenicity test using immunodeficient mice was conducted in Epicel ® [20] , JACE [27] and JACC [28] . The risk-based approach would be the best way to develop a novel class product including human cells and tissue products. Adaptive licensing [51] and the conditional/timelimited approval system [45] should lessen the development period and review time for human cells and tissue products.
There are limitations to this study. We examined nine autologous human cells and tissue products in the US, EU and Japan. When more than 20 products are approved, further study should be conducted to compare the global evaluation system to determine an efficient and timely manner to deliver new product to patients. Further analyses should compare the requirements of those products and the regulatory safety among the agencies, including adverse reaction reporting such as the FDA MedWatch mandatory reporting [64] , EudraVigilance [65] and Postmarketing Safety [66] , during the postmarket surveillance because some of the premarket clinical trials did not include a sufficient patient population to be clarified the safety issues.
Conclusion
Autologous human cells and tissue products in the US, the EU and Japan were approved for market authorization using various kinds of premarket application system. The preapproval clinical evaluations were conducted with small population or using clinical experience, while most of allogeneic human cells and tissue products were approved for market authorization using relatively larger clinical trials. The clinical evaluation of the autologous human cells and tissue products would focus on postmarket-oriented evaluation to distribute the new products of regenerative medicine, tissue engineering, and cell therapy to patients and to oversee the risk of these products using registry.
